Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Citrome

Showing results (11-20 of 441) with videos related to

Pageof 45
Sort By:
International Journal of Clinical Practice|July 11, 2019
Our impact factor went from 2.000 to 2.613: So what?Leslie Citrome
Evidence-Based Mental Health|June 28, 2018
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesiaLeslie Citrome
Postgraduate Medicine|January 4, 2003
Atypical antipsychotics for acute agitation. New intramuscular options offer advantagesLeslie Citrome
Schizophrenia Research|October 22, 2011
Treatment-resistant schizophrenia: what's nextLeslie Citrome
International Journal of Clinical Practice|November 29, 2018
International Journal of Clinical Practice: What was hot in 2018?Leslie Citrome
The International Journal of Neuropsychopharmacology|April 27, 2005
Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitusLeslie Citrome
CNS Spectrums|November 4, 2025
Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide - ERRATUMLeslie Citrome
Expert Opinion on Drug Safety|November 10, 2025
What's in a name? What shall we call xanomeline-trospium combination?Leslie Citrome
Advances in Therapy|January 31, 2013
Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapyLeslie Citrome
Expert Review of Neurotherapeutics|August 1, 2013
New second-generation long-acting injectable antipsychotics for the treatment of schizophreniaLeslie Citrome
Pageof 45

Showing results (11-20 of 441) with videos related to

Sort By:
Pageof 45
International Journal of Clinical Practice|July 11, 2019
Our impact factor went from 2.000 to 2.613: So what?Leslie Citrome
Evidence-Based Mental Health|June 28, 2018
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesiaLeslie Citrome
Postgraduate Medicine|January 4, 2003
Atypical antipsychotics for acute agitation. New intramuscular options offer advantagesLeslie Citrome
Schizophrenia Research|October 22, 2011
Treatment-resistant schizophrenia: what's nextLeslie Citrome
International Journal of Clinical Practice|November 29, 2018
International Journal of Clinical Practice: What was hot in 2018?Leslie Citrome
The International Journal of Neuropsychopharmacology|April 27, 2005
Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitusLeslie Citrome
CNS Spectrums|November 4, 2025
Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide - ERRATUMLeslie Citrome
Expert Opinion on Drug Safety|November 10, 2025
What's in a name? What shall we call xanomeline-trospium combination?Leslie Citrome
Advances in Therapy|January 31, 2013
Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapyLeslie Citrome
Expert Review of Neurotherapeutics|August 1, 2013
New second-generation long-acting injectable antipsychotics for the treatment of schizophreniaLeslie Citrome
Pageof 45